PTSD Prevention Using Oral Hydrocortisone
Key facts
- Who runs it
- Rachel Yehuda
- Where
- New York, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 201 people enrolled
- Started
- 12 Jan 2022
- Ended
- 6 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo
- Hydrocortisone
- Record updated
- 19 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age ≥ 18 years
- Weight: 99 lb - 242 lbs
- Experienced a traumatic event less than 6 hours ago; Secondary Inclusion Criteria:; ED staff note marked anxiety emotional distress and or dissociation in relation to index trauma as assessed by meeting a minimum of 2 out of 4 of the peritraumatic characteristics that have been associated with the development of PTSD below:
- Anxiety Visual Analog Scale minimum score of 4 on a scale of 0 to 10
- Peritraumatic dissociation (PDEQ) with a cut-point of 15 (lowest possible score is 10)
- Peritraumatic distress (Peritraumatic Distress Inventory) (PDI) with a cut-point of 15 (lowest possible score is 0)
- Heart rate at 80 bpm or more
Who cannot take part
- Currently taking oral steroids
- Individuals prescribed a narcotic medication to alleviate acute pain in the ED will not be eligible to participate in the treatment study
- Severe physical injury as assessed with the Abbreviated Injury Scale (AIS > 2); Examples include severe burn injury, life-threatening medical or surgical condition, condition requiring surgical intervention under general anesthesia, as indicated by clinical judgment
- Medical conditions e.g., Cushing's syndrome, current acute infectious or viral disease, tuberculosis, unstable diabetes or hypertension, myasthenia gravis, heart failure
- Reported diagnoses of schizophrenia, bipolar I disorder, or other psychotic illness
- Current or past history of dementia, amnesia or other cognitive disorder predating trauma exposure
- Inability to provide informed consent or cooperate with the screening or collection of initial measures
- Intoxication to a degree that would interfere with the ability to provide informed consent or high level or intoxication reported at the time of trauma
- Moderate to severe head injury associated with current trauma exposure as defined by a loss of consciousness >30 minutes following injury
- Use of benzodiazepine within 24 hours of trauma exposure will not be eligible to participate in the study
- Weight below 45kg or above 110 kg (99 lbs - 242 lbs)
- Pregnancy (a urine pregnancy test will be performed in the ED)
- Individuals experiencing on-going trauma (i.e., domestic violence)
- Residence outside local area, which would hinder attendance at follow up visits due to long travel time
Where in United States
Also in 1 other country, 1 site
- Icahn School of Medicine at Mount SinaiNew York, United States
- Mount Sinai Morningside Emergency DepartmentNew York, United States
About the trial
What the trial wants to find out
There is currently no evidence-based intervention for individuals exposed to trauma that is designed to aid recovery and prevent the development of post-traumatic stress disorder (PTSD). This randomized control trial proposes to test a one-time prophylactic treatment for the prevention of symptoms of PTSD and related mental health disturbances and the promotion of resilience using a single dose of hydrocortisone (HCORT) or placebo, administered within six hours of trauma exposure. People at risk for PTSD have demonstrated low cortisol levels before and in the aftermath of traumatic exposures and lower cortisol levels have also been observed in combat veterans with PTSD. Administering HCORT at the time of trauma would help boost the body's natural stress recovery systems to facilitate resilience.
Read full original descriptionShow less
Participants who present to the emergency department following trauma exposure and report high distress, panic, anxiety or dissociation will be invited to participate in this clinical trial. 220 trauma survivors will be randomized and recruited at two locations: Mount Sinai Hospital in New York City, US, and a civilian/military hospital in Tel Hashomer, Israel. Trauma survivors will be assessed at 2, 6, 12 and 28 weeks post-treatment. HCORT closely resembles cortisol produced in the adrenal glands and released during stress.
It is hypothesized that HCORT treatment will result in an accelerated decline in the presence and severity of PTSD and related mental health symptoms compared to the placebo group. Blood samples will be collected for analysis of potential biomarkers to obtain more information about the mechanisms of action of this intervention. The information obtained will be relevant in determining whether early intervention with a single dose of HCORT, compared to placebo, administered within several hours following trauma exposure, will reduce the risk of developing PTSD in trauma survivors.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
matching capsule PO
- HCORTExisting treatment, for comparison
180 mg capsule PO
Treatment: Hydrocortisone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PTSD Prevention Using Oral Hydrocortisone in the Immediate Aftermath of Trauma
- Publications
- Early pharmacological interventions for prevention of post-traumatic stress disorder (PTSD) in individuals experiencing acute traumatic stress symptoms.The Cochrane database of systematic reviews, 2024
- Record updated
- 19 March 2026